Skip to content

Study · Case report or series · n = 1 · 2015

1 result

Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty.

Akın O, Yavuz ST, Hacıhamdioğlu B, Sarı E, Gürsel O, Yeşilkaya E

Journal of pediatric endocrinology & metabolism : JPEM1 Nov 2015Cited by 6 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In an 8-year-old girl with central precocious puberty, intravenous gonadorelin acetate caused severe anaphylaxis with loss of consciousness and tonic seizures within 3 minutes.

    In plain wordsIn one 8-year-old girl with early puberty, gonadorelin acetate given into a vein caused a severe allergic reaction within minutes.

    Outcome
    Not applicableAnaphylaxis after intravenous gonadorelin acetate
    Study

    n = 1

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Herein, we described - to the best of our knowledge - the first pediatric case in which severe anaphylaxis was encountered after intravenous gonadorelin acetate administration.
    2 context sentences
    Summary · context
    Within 3 min after intravenous administration of gonadorelin acetate, she lost consciousness and tonic seizures began in her hands and feet.
    Summary · context
    An 8-year-old girl who was diagnosed with central precocious puberty was receiving triptorelin acetate treatment uneventfully for 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.